These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 9763005)
1. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005 [TBL] [Abstract][Full Text] [Related]
2. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287 [TBL] [Abstract][Full Text] [Related]
3. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771 [TBL] [Abstract][Full Text] [Related]
4. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088 [TBL] [Abstract][Full Text] [Related]
5. High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging. Panagiotidis E; Datseris IE; Exarhos D; Skilakaki M; Skoura E; Bamias A Nucl Med Commun; 2012 Apr; 33(4):431-8. PubMed ID: 22293498 [TBL] [Abstract][Full Text] [Related]
6. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
7. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613 [TBL] [Abstract][Full Text] [Related]
8. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962 [TBL] [Abstract][Full Text] [Related]
9. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer? Schaefferkoetter JD; Carlson ER; Heidel RE J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746 [TBL] [Abstract][Full Text] [Related]
10. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. Park JW; Jo MK; Lee HM BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371 [TBL] [Abstract][Full Text] [Related]
11. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases. Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452 [TBL] [Abstract][Full Text] [Related]
13. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Thrall MM; DeLoia JA; Gallion H; Avril N Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284 [TBL] [Abstract][Full Text] [Related]
14. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer. Roh JL; Ryu CH; Kim JS; Lee JS; Choi SH; Nam SY; Kim SY Oral Oncol; 2007 Sep; 43(8):757-63. PubMed ID: 17112773 [TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. Ardito A; Massaglia C; Pelosi E; Zaggia B; Basile V; Brambilla R; Vigna-Taglianti F; Duregon E; Arena V; Perotti P; Penna D; Terzolo M Eur J Endocrinol; 2015 Dec; 173(6):749-56. PubMed ID: 26346137 [TBL] [Abstract][Full Text] [Related]
16. FDG PET/CT in the detection of recurrent rectal cancer. Kau T; Reinprecht P; Eicher W; Lind P; Starlinger M; Hausegger KA Int Surg; 2009; 94(4):315-24. PubMed ID: 20302028 [TBL] [Abstract][Full Text] [Related]
17. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Schaffler GJ; Wolf G; Schoellnast H; Groell R; Maier A; Smolle-Jüttner FM; Woltsche M; Fasching G; Nicoletti R; Aigner RM Radiology; 2004 Jun; 231(3):858-65. PubMed ID: 15105451 [TBL] [Abstract][Full Text] [Related]
18. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Graafland NM; Leijte JA; Valdés Olmos RA; Hoefnagel CA; Teertstra HJ; Horenblas S Eur Urol; 2009 Aug; 56(2):339-45. PubMed ID: 19477581 [TBL] [Abstract][Full Text] [Related]